Table 2.
Antitumor activity in IMDC intermediate- and high-risk patients after the start of sunitinib
| ILIXA/SUN group (n = 45a) | SUN group (n = 25) | |
|---|---|---|
| Confirmed objective response rate (%) | 19 (42.2) | 6 (24.0) |
| Complete response | 3 (6.7) | 0 (0.0) |
| Partial response | 16 (35.6) | 6 (24.0) |
| Stable disease | 11 (24.4) | 10 (40.0) |
| Progressive disease | 7 (15.6) | 2 (8.0) |
| Unable to determine or not reported | 9 (20.0) | 7 (28.0) |
| Time to response (mo), median (95% CI) | 2.9 (2.6–6.5) | 4.2 (2.9–9.6) |
CI = confidence interval; ILIXA = ilixadencel; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; SUN = sunitinib.
a
One patient was not evaluable for response evaluation due to which no evaluation by imaging was performed.